Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody

被引：7

作者：

Okamoto, M ^{[1
]}

Akioka, K

Higuchi, A

Kadotani, Y

Ushigome, H

Uryuhara, K

Kaihara, S

Yoshimura, N

机构：

[1] Kyoto Prefectural Univ Med, Dept Organ Interact Res Med, Kamigyo Ku, Kyoto 6028566, Japan

[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Transplantat & Regenerat Surg, Kyoto 6028566, Japan

来源：

CLINICAL TRANSPLANTATION | 2005年 / 19卷

关键词：

anti-CD25 monoclonal antibody; kidney transplantation; protocol biopsy;

D O I：

10.1111/j.1399-0012.2005.00404.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Twenty-seven living-donor kidney recipients were treated with the antibody against CD25 as the induction immunosuppressive agent. They did not develop acute rejection within 1 month after transplantation, and mean serum creatinine level at 1 month was 1.0 +/- 0.4 mg/dL. There were no findings of acute rejection or drug-induced nephrotoxity in protocol biopsies at 1 month following transplantation. After 1 month had passed, acute rejection occurred in three cases. The pathological grade of acute rejection varied from borderline to grade III by Banff classification. The careful inspection is necessary to find out the occurrences of acute rejection more than 2 months after transplantation because immunological situation has been changing around this period.

引用

页码：49 / 53

页数：5

共 50 条

[31] Anti-CD25 monoclonal antibody modulates cytokine expression and prolongs allografts survival in rats cardiac transplantation
夏家红
蒋雄刚
黄毅
张凯伦
肖诗亮
杨辰垣
ChineseMedicalJournal, 2003, (03)
[32] Phase I Trial of WuTac, a Murine Anti-CD25 Monoclonal Antibody, Tolerance AND Pharmacokinetics of Multiple Doses in Chinese Renal Transplant Patients
Yang, H.
Li, H.
Wang, Z.
Zeng, F.
Zhang, A.
Zhang, N.
Sun, K.
Li, W.
Du, W.
Hu, Y.
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 354 - 354
[33] The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study
Becker, M. O.
Brueckner, C.
Scherer, H. U.
Wassermann, N.
Humrich, J. Y.
Hanitsch, L. G.
Schneider, U.
Kawald, A.
Hanke, K.
Burmester, G. R.
Riemekasten, G.
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (07) : 1340 - U186
[34] Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?
Bayes, B.
Pastor, M. C.
Lauzurica, R.
Granada, M. L.
Salinas, I.
Romero, R.
TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2248 - 2250
[35] MONOCLONAL ANTI-CD25 FOR ACUTE REJECTION AFTER LIVER-TRANSPLANTATION
OTTO, G
THIES, J
KRAUS, T
MANNER, M
HERFARTH, C
HOFMANN, WJ
SCHLAG, H
MEUER, S
LANCET, 1991, 338 (8760): : 195 - 195
[36] Anti-CD25 treated cardiac allograft recipients acutely reject their graft via the IL-15 route
Baan, CC
van Gelder, T
Maat, APWM
Balk, AHMM
Weimar, W
TRANSPLANTATION, 1999, 67 (07) : S22 - S22
[37] Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activity
Stickler, Marcia
Reddy, Anita
Xiong, Joanna M.
Wong, Melanie H.
Akamatsu, Yoshiko
Hinton, Paul R.
Harding, Fiona A.
PROTEIN ENGINEERING DESIGN & SELECTION, 2019, 32 (12): : 543 - 554
[38] Cutting edge:: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+ CD25+ T regulatory cells
Kohm, Adam P.
McMahon, Jeffrey S.
Podojil, Joseph R.
Begolka, Wendy Smith
DeGutes, Mathew
Kasprowicz, Deborah J.
Ziegler, Steven F.
Miller, Stephen D.
JOURNAL OF IMMUNOLOGY, 2006, 176 (06): : 3301 - 3305
[39] A experimental study and clinical result of prophylaxis aGVHD with humanized anti-CD25 monoclonal antibody in haploidentical BMT.
Ji, SQ
Chen, HR
Wang, HX
Yan, HM
Xue, M
Liu, J
Xun, CQ
BLOOD, 2004, 104 (11) : 353A - 354A
[40] Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
Hong, JC
Kahan, BD
TRANSPLANTATION, 1999, 68 (05) : 701 - 704

← 1 2 3 4 5 →